PPT-Improving Therapy Outcomes in Relapsed/Refractory

Hodgkin Lymphoma Program Objectives Brentuximab Vedotin in Hodgkin Lymphoma Brentuximab Vedotin in Patients With RR HL Brentuximab Vedotin Adverse Events Nivolumab in RelapsedRefractory HL Pembrolizumab in RelapsedRefractory HL. Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . 5 Multiple Myeloma SANDRA E. KURTIN, RN, MS, AOCN Ruben Niesvizky. Myeloma Center. Myelomacenter.org. run9001@med.cornell.edu. Multiple Myeloma: Natural History of Disease. Durie B; International Myeloma Foundation. . Concise review of the disease and treatment options: multiple myeloma. 2011/2012 edition;. therapy in relapsed/refractory myeloma: . A UK multi-centre experience. Neil Rabin. Consultant Haematologist. o. n behalf of Dr Nicola . Maciocia. University College London Hospitals, UK. 4. th. November 2015. Refractory Multiple Myeloma. Case #1. Monitoring Post-ASCT. Blood Testing. Other Monitoring After Initial Therapy. Case #1 (cont). Assessment at Relapse. Symptomatic First Relapse. Cytogenetic Testing at Relapse. IWCLL Criteria for Treating CLL. Other Considerations at Relapse. Risk Factors at Relapse. IGHV . Status Affects Clinical Course. Case 1: 65-Year-Old Man. Assessing This Patient's Options. TP53 . Mutation/del(17p) and CIT. A . new approach to commissioning integrated provision. Governing Body . 7 October 2014. Phase 1: Case for Change (Sept 2013, GB). Burning . Platform. Inherited . challenges on . (i) service quality and (ii) finances. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. MSc. University of Tennessee College of . Health Sciences. Memphis, TN. . . Learning Objectives. Upon completion, participants should be able to:. Review treatment regimens for patients with relapsed ALL. Case Discussion A 64-year old woman diagnosed with monoclonal gammopathy of undetermined significance (MGUS ) in September 2015 She has been monitored over time and has had a slight increase in her proteins. T. ransplant . in CR on . B. rentuximab. . V. edotin. : . Allo. . Transplant . or . Maintenance . T. herapy. ?. Anas Younes, M.D.. Memorial Sloan Kettering Cancer Center. Overall Survival. <1990 median 1.9 yrs. Bertrand Coiffier. Service d. ’. Hématologie. Hospices Civils de Lyon. Equipe . « Pathologie des Cellules Lymphoïdes ». UMR 5239 CNRS – UCB – ENS - HCL. The Lymphoma. Study Association. One question, lot of possibilities. Jonathon B. Cohen, MD. Dept of . Hematology. /Medical Oncology. Co-Director . Lymphoma Program. Relapsed aggressive . nhl. associated with shortened survival. Scholar-1 (Crump et al, Blood 2017). Martin et al, Blood 2016. Chimeric Antigen Receptor Tcell TherapyClinical Guideline Effective August 4, 2022 ��Table of Contents��THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL TO OPTUMUnauthorized u